nach oben

Erschienen in:

01.07.2014 | Clinical Trial

Early myocardial deformation abnormalities in breast cancer survivors

verfasst von: Ben F. Bulten, Annelies M. C. Mavinkurve-Groothuis, Lioe-Fee de Geus-Oei, Anton F. J. de Haan, Chris L. de Korte, Louise Bellersen, Hanneke W. M. van Laarhoven, Livia Kapusta

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

To evaluate the role of 2D myocardial strain (rate) imaging in the detection of early subclinical cardiotoxicity in breast cancer survivors treated with an anthracycline-based chemotherapeutic regimen. 57 adult breast cancer survivors were analyzed 1 year after therapy. All patients underwent biomarker analysis and 2D echocardiography consisting of conventional echocardiographic and strain (rate) parameters. Conventional echocardiographic values were normal. Global longitudinal strain was normal, but 18 % of patients showed a >2 SD decrease when individually compared to reference values. This subgroup showed a decrease in end-systolic and end-diastolic volumes and an increase in left ventricular mass. Radial and circumferential strain rates were significantly decreased in the whole study group. 2D myocardial strain (rate) imaging showed abnormalities in breast cancer survivors, while conventional echocardiographic values remained normal, rendering 2D myocardial strain (rate) imaging an interesting tool for the early detection of anthracycline-induced cardiotoxicity.

Stoodley PW, Richards DA, Hui R, Boyd A, Harnett PR, Meikle SR, Clarke J, Thomas L (2011) Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. Eur J Echocardiogr 12:945–952. doi:10.1093/ejechocard/jer187 PubMedCrossRef

Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE (2005) Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131:561–578. doi:10.1111/j.1365-2141.2005.05759.x PubMedCrossRef

Chargari C, Kirov KM, Bollet MA, Magne N, Vedrine L, Cremades S, Beuzeboc P, Fourquet A, Kirova YM (2011) Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment. Cancer Treat Rev 37:321–330. doi:10.1016/j.ctrv.2010.08.007 PubMedCrossRef

Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808–3815. doi:10.1200/JCO.2006.10.4976 PubMedCrossRef

Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, Orav EJ, Gelber RD, Colan SD (1995) Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1556–1738CrossRef

Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB (2008) Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 26:3777–3784. doi:10.1200/JCO.2007.14.9401 PubMedCentralPubMedCrossRef

Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229. doi:10.1124/pr.56.2.6 PubMedCrossRef

Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:2231–2247PubMedCrossRef

Mavinkurve-Groothuis AM (2012) Anthracycline-induced cardiotoxicity. Early detection with new strategies. Radboud University, Nijmegen

10.

Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA (2009) Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 10:391–399. doi:10.1016/S1470-2045(09)70042-7 PubMedCrossRef

11.

de Geus-Oei LF, Mavinkurve-Groothuis AM, Bellersen L, Gotthardt M, Oyen WJ, Kapusta L, van Laarhoven HW (2011) Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity. J Nucl Med 52:560–571. doi:10.2967/jnumed.110.082784 PubMed

12.

McGowan JH, Cleland JG (2003) Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods. Am Heart J 146:388–397. doi:10.1016/S0002-8703(03)00248-5 PubMedCrossRef

13.

Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH (2013) Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 61:77–84. doi:10.1016/j.jacc.2012.09.035 PubMedCrossRef

14.

Mavinkurve-Groothuis AM, Groot-Loonen J, Marcus KA, Bellersen L, Feuth T, Bokkerink JP, Hoogerbrugge PM, de Korte C, Kapusta L (2010) Myocardial strain and strain rate in monitoring subclinical heart failure in asymptomatic long-term survivors of childhood cancer. Ultrasound Med Biol 36:1783–1791. doi:10.1016/j.ultrasmedbio.2010.08.001 PubMedCrossRef

15.

Jurcut R, Wildiers H, Ganame J, D’Hooge J, De Backer J, Denys H, Paridaens R, Rademakers F, Voigt JU (2008) Strain rate imaging detects early cardiac effects of pegylated liposomal doxorubicin as adjuvant therapy in elderly patients with breast cancer. J Am Soc Echocardiogr 21:1283–1289. doi:10.1016/j.echo.2008.10.005 PubMedCrossRef

16.

Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M (2012) Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5:596–603. doi:10.1161/CIRCIMAGING.112.973321 PubMedCentralPubMedCrossRef

17.

Florescu M, Magda LS, Enescu OA, Jinga D, Vinereanu D (2014) Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer. J Am Soc Echocardiogr 27:83–92. doi:10.1016/j.echo.2013.10.008 PubMedCrossRef

18.

Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH (2013) Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging 15(3):324–331PubMedCrossRef

19.

Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463. doi:10.1016/j.echo.2005.10.005 PubMedCrossRef

20.

Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 10:165–193. doi:10.1093/ejechocard/jep007 PubMedCrossRef

21.

Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57:450–458PubMedCrossRef

22.

Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quinones MA (1997) Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 30:1527–1533PubMedCrossRef

23.

Leitman M, Lysyansky P, Sidenko S, Shir V, Peleg E, Binenbaum M, Kaluski E, Krakover R, Vered Z (2004) Two-dimensional strain-a novel software for real-time quantitative echocardiographic assessment of myocardial function. J Am Soc Echocardiogr 17:1021–1029. doi:10.1016/j.echo.2004.06.019 PubMedCrossRef

24.

Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS, American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging (2002) Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 105:539–542PubMedCrossRef

25.

Berne RM, Levy MN (1993) Physiology. Mosby, St. Louis

26.

Dalen H, Thorstensen A, Aase SA, Ingul CB, Torp H, Vatten LJ, Stoylen A (2010) Segmental and global longitudinal strain and strain rate based on echocardiography of 1266 healthy individuals: the HUNT study in Norway. Eur J Echocardiogr 11:176–183. doi:10.1093/ejechocard/jep194 PubMedCrossRef

27.

Hess G, Runkel S, Zdunek D, Hitzler WE (2005) Reference interval determination for N-terminal-B-type natriuretic peptide (NT-proBNP): a study in blood donors. Clin Chim Acta 360:187–193. doi:10.1016/j.cccn.2005.04.031 PubMedCrossRef

28.

Ho E, Brown A, Barrett P, Morgan RB, King G, Kennedy MJ, Murphy RT (2010) Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart 96:701–707. doi:10.1136/hrt.2009.173997 PubMedCrossRef

29.

Migrino RQ, Aggarwal D, Konorev E, Brahmbhatt T, Bright M, Kalyanaraman B (2008) Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography. Ultrasound Med Biol 34:208–214. doi:10.1016/j.ultrasmedbio.2007.07.018 PubMedCentralPubMedCrossRef

30.

Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, Gosavi S, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M (2011) Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 107:1375–1380. doi:10.1016/j.amjcard.2011.01.006 PubMedCentralPubMedCrossRef

31.

Risum N, Ali S, Olsen NT, Jons C, Khouri MG, Lauridsen TK, Samad Z, Velazquez EJ, Sogaard P, Kisslo J (2012) Variability of global left ventricular deformation analysis using vendor dependent and independent two-dimensional speckle-tracking software in adults. J Am Soc Echocardiogr 25:1195–1203. doi:10.1016/j.echo.2012.08.007 PubMedCrossRef

32.

Telli ML, Hunt SA, Carlson RW, Guardino AE (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25:3525–3533. doi:10.1200/JCO.2007.11.0106 PubMedCrossRef

33.

Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH (2009) Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am Heart J 158:294–301. doi:10.1016/j.ahj.2009.05.031 PubMedCrossRef

34.

Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE (1998) Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 27:53–68PubMedCrossRef

35.

Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD (2005) Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 23:2629–2636. doi:10.1200/JCO.2005.12.121 PubMedCrossRef

36.

Steinherz LJ, Steinherz PG, Tan C (1995) Cardiac failure and dysrhythmias 6–19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 24:352–361PubMedCrossRef

37.

Bernaba BN, Chan JB, Lai CK, Fishbein MC (2010) Pathology of late-onset anthracycline cardiomyopathy. Cardiovasc Pathol 19:308–311. doi:10.1016/j.carpath.2009.07.004 PubMedCrossRef

38.

Shapiro CL, Hardenbergh PH, Gelman R, Blanks D, Hauptman P, Recht A, Hayes DF, Harris J, Henderson IC (1998) Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 16:3493–3501PubMed

39.

Cuzick J, Stewart H, Rutqvist L, Houghton J, Edwards R, Redmond C, Peto R, Baum M, Fisher B, Host H et al (1994) Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 12:447–453PubMed

40.

Erven K, Florian A, Slagmolen P, Sweldens C, Jurcut R, Wildiers H, Voigt JU, Weltens C (2012) Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2012.09.022

41.

Malhotra V, Dorr VJ, Lyss AP, Anderson CM, Westgate S, Reynolds M, Barrett B, Perry MC (2004) Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer. Clin Breast Cancer 5:377–384PubMedCrossRef

42.

Aihara T, Takatsuka Y, Itoh K, Sasaki Y, Katsumata N, Watanabe T, Noguchi S, Horikoshi N, Tabei T, Sonoo H, Hiraki S, Inaji H (2003) Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer. Oncology 64:124–130PubMedCrossRef

43.

Gamucci T, D’Ottavio AM, Magnolfi E, Barduagni M, Vaccaro A, Sperduti I, Moscetti L, Belli F, Meliffi L (2007) Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer. Br J Cancer 97:1040–1045. doi:10.1038/sj.bjc.6603982 PubMedCentralPubMedCrossRef

44.

Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J (1981) Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 141:758–763PubMedCrossRef

45.

Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT (1991) Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 9:1215–1223PubMed

46.

Horacek JM, Pudil R, Jebavy L, Tichy M, Zak P, Maly J (2007) Assessment of anthracycline-induced cardiotoxicity with biochemical markers. Exp Oncol 29:309–313PubMed

47.

Romano S, Fratini S, Ricevuto E, Procaccini V, Stifano G, Mancini M, Di Mauro M, Ficorella C, Penco M (2011) Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer 105:1663–1668. doi:10.1038/bjc.2011.439 PubMedCentralPubMedCrossRef

Titel: Early myocardial deformation abnormalities in breast cancer survivors
verfasst von: Ben F. Bulten
Annelies M. C. Mavinkurve-Groothuis
Lioe-Fee de Geus-Oei
Anton F. J. de Haan
Chris L. de Korte
Louise Bellersen
Hanneke W. M. van Laarhoven
Livia Kapusta
Publikationsdatum: 01.07.2014
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2014
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-014-2997-4

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Early myocardial deformation abnormalities in breast cancer survivors

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

Body mass index, diabetes, and triple-negative breast cancer prognosis

A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients

The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer

Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie